TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04804592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tactile Esthesiometer Prototype
Description: A round plastic nozzle (1.8mm diameter) used as a stimulus for corneal sensation threshold measurement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tactile Esthesiometer Prototype
Description: A round plastic nozzle (1.8mm diameter) used as a stimulus for corneal sensation threshold measurement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tactile Esthesiometer Prototype
Description: A round plastic nozzle (1.8mm diameter) used as a stimulus for corneal sensation threshold measurement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liquid Jet Esthesiometer Prototype
Description: Balanced salt solution with a pH value similar to the tear film uesd as a liquid jet stimulus for corneal sensation threshold measurement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liquid Jet Esthesiometer Prototype
Description: Balanced salt solution with a pH value similar to the tear film uesd as a liquid jet stimulus for corneal sensation threshold measurement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liquid Jet Esthesiometer Prototype
Description: Balanced salt solution with a pH value similar to the tear film uesd as a liquid jet stimulus for corneal sensation threshold measurement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochet Bonnet esthesiometer
Description: A nylon thread (0.12mm diameter) used as a stimulus for corneal sensation threshold measurement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochet Bonnet esthesiometer
Description: A nylon thread (0.12mm diameter) used as a stimulus for corneal sensation threshold measurement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochet Bonnet esthesiometer
Description: A nylon thread (0.12mm diameter) used as a stimulus for corneal sensation threshold measurement
Study: NCT05888350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclometasone Dipropionate and Formoterol Inhalation Aerosol
Description: Inhaled Foster (Beclometasone Dipropionate and Formoterol Inhalation Aerosol) , 1puff, BID, 4weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled Placebo, 1puff, BID, 4weeks
Study: NCT04738357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542
Description: HSK21542：1 µg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05065398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX208
Description: 450mg bid, take orally
Study: NCT05633810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 40 mg non-enteric-coated tablet taken twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: 40 mg non-enteric-coated tablet taken twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin Placebo
Description: non-enteric-coated tablet taken twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin Placebo
Description: non-enteric-coated tablet taken twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 0.5 mg tablet taken once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine
Description: 0.5 mg tablet taken once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 0.5 mg tablet taken once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine
Description: 0.5 mg tablet taken once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine Placebo
Description: tablet taken once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine Placebo
Description: tablet taken once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine Placebo
Description: tablet taken once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine Placebo
Description: tablet taken once daily.
Study: NCT06089447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A story based intervention called 'The Shadow of Tallystick Valley'
Description: 'The Shadows of Tallystick Valley' is a story based intervention for CYP aged 7 - 14 years aimed at supporting the psychological wellbeing and resilience of those affected by familial substance misuse. It has been designed by Book of Beasties, a developer of games and educational content, in collaboration with the charity Change Grow Live, who support those experiencing substance misuse and CYP affected by familial substance misuse in the UK. The wellbeing resource harnesses protective factors, such as respectful and caring conversations with professionals (Wangansteen and Westby, 2019), to facilitate a safe and supportive environment aimed towards understanding the CYPs experience, support their psychological wellbeing and building resilience and coping skills. It uses fictional narratives, including characters that represent particular topics which act as drivers for engagement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A story based intervention called 'The Shadow of Tallystick Valley'
Description: 'The Shadows of Tallystick Valley' is a story based intervention for CYP aged 7 - 14 years aimed at supporting the psychological wellbeing and resilience of those affected by familial substance misuse. It has been designed by Book of Beasties, a developer of games and educational content, in collaboration with the charity Change Grow Live, who support those experiencing substance misuse and CYP affected by familial substance misuse in the UK. The wellbeing resource harnesses protective factors, such as respectful and caring conversations with professionals (Wangansteen and Westby, 2019), to facilitate a safe and supportive environment aimed towards understanding the CYPs experience, support their psychological wellbeing and building resilience and coping skills. It uses fictional narratives, including characters that represent particular topics which act as drivers for engagement.
Study: NCT05483153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant-Directed Singing Coaching
Description: At-risk mothers will receive four, 30-minute, in-person infant-directed singing coaching intervention sessions that take place over two weeks. Mothers will learn how to better read infant cues and respond with sensitive singing. Infants will gain experience in self-regulation of arousal states.
Study: NCT05000515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-resistance inspiratory muscle strength training
Description: Participants will perform inspiratory muscle strength training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Participants will perform brisk walking.
Study: NCT06156865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to address late talking
Description: this intervention is designed to support both speech and language development in children who are toddlers. Given the age group of children their parents are part of the intervention program. Importantly the frequency of the intervention can range from once to twice per week, with timing also designed to complement the particular agency
Study: NCT05325320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMI/SIA Stigma Reduction Intervention
Description: Online course designed to reduce stigma behaviors towards serious mental illness and suicide ideation and attempt among medical students. It aims to improve medical students' healthcare delivery skills.

Intervention type: OTHER
Group type: OTHER
Intervention: Disaster Preparedness Course
Description: Online course designed to improve professionals' skills and competencies for engaging in disaster preparedness.
Study: NCT05097586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: 2mA of direct current delivered in 15 sessions lasting 30 minutes each over 3 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: workbook
Description: Self-directed depression in pregnancy workbook completed during each session to control the in-session brain state

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: workbook
Description: Self-directed depression in pregnancy workbook completed during each session to control the in-session brain state

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Sham stimulation in which the current turns off after 30 seconds in a slow ramp down that mirrors sensory adaptation in ongoing stimulation, delivered in 15 sessions lasting 30 minutes each over 3 weeks
Study: NCT05061303

Intervention type: OTHER
Intervention: Assessment of the drug concentration in the blood
Description: The material in the study will be blood, in which tacrolimus concentrations will be measured at the following time points: 0, 2hours, 6hours, 12hours after drug administration, without taking omeprazole/famotidine and then the next day after taking the protective drug in same time points, without 12hours. Sequentially routinely in the so-called point T0 before taking the drug (12 hours after the last dose) during follow-up visits at the Transplant Outpatient Clinic.

Intervention type: OTHER
Intervention: Assessment of the drug concentration in the blood
Description: The material in the study will be blood, in which tacrolimus concentrations will be measured at the following time points: 0, 2hours, 6hours, 12hours after drug administration, without taking omeprazole/famotidine and then the next day after taking the protective drug in same time points, without 12hours. Sequentially routinely in the so-called point T0 before taking the drug (12 hours after the last dose) during follow-up visits at the Transplant Outpatient Clinic.
Study: NCT06333873

Intervention type: OTHER
Group type: OTHER
Intervention: patient-reported outcome
Description: Performance of real-life tests and tasks

Intervention type: OTHER
Group type: OTHER
Intervention: patient-reported outcome
Description: Performance of real-life tests and tasks

Intervention type: OTHER
Group type: OTHER
Intervention: patient-reported outcome
Description: Performance of real-life tests and tasks

Intervention type: OTHER
Group type: OTHER
Intervention: patient-reported outcome
Description: Performance of real-life tests and tasks
Study: NCT05136963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: 5 milliliter of iohexol will be administrated.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pharmacokinetics
Description: 10 blood samples of 5 milliliter will be performed. sampling time ater administration of Iohexol: 00h30, 1h00, 1h30, 02h00, 03h00, 04h00, 05h00, 06h00, 09h00 and 12h00
Study: NCT05563896

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06467812

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salt Tablets
Description: Three doses of 4 Salt Tablets (1gm) will be taken with 400mL of water on day 2 (1200ml total) between \~8am and \~12pm during the testing day, which runs from \~7am to \~3:30pm.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Electrolyte Solution
Description: Three doses of 400mL of the Electrolyte Solution dissolved in water (1200 mL total) will be consumed on day 3 between \~8am and \~12pm during the testing day, which runs from \~7am to \~3:30pm. On day 4 the Electrolyte Solution Single Bolus will be consumed in a single dose of 1200mL at \~12pm during the testing day.~The ingredients are included below for the two flavors offered.~Orange flavor: Water, Dextrose with Maltodextrin, Aspartame, Acesulfame Potassium, Sodium Citrate, Salt, Citric Acid, Maltodextrin, Natural Flavor, Calcium Phosphate, Contains less than 2% Of Ascorbic Acid (Vitamin C), Artificial Flavor, Artificial Color, Red 40, Yellow 5, BHA (Butylated Hydroxyanisole).~Lemonade flavor: Water, Dextrose with Maltodextrin, Aspartame, Acesulfame Potassium, Sodium Citrate, Salt, Citric Acid, Calcium Phosphate, Maltodextrin, Contains less than 2% Of Ascorbic Acid (Vitamin C), Natural Flavor, Artificial Color, Yellow 5, BHA.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Electrolyte Solution
Description: Three doses of 400mL of the Electrolyte Solution dissolved in water (1200 mL total) will be consumed on day 3 between \~8am and \~12pm during the testing day, which runs from \~7am to \~3:30pm. On day 4 the Electrolyte Solution Single Bolus will be consumed in a single dose of 1200mL at \~12pm during the testing day.~The ingredients are included below for the two flavors offered.~Orange flavor: Water, Dextrose with Maltodextrin, Aspartame, Acesulfame Potassium, Sodium Citrate, Salt, Citric Acid, Maltodextrin, Natural Flavor, Calcium Phosphate, Contains less than 2% Of Ascorbic Acid (Vitamin C), Artificial Flavor, Artificial Color, Red 40, Yellow 5, BHA (Butylated Hydroxyanisole).~Lemonade flavor: Water, Dextrose with Maltodextrin, Aspartame, Acesulfame Potassium, Sodium Citrate, Salt, Citric Acid, Calcium Phosphate, Maltodextrin, Contains less than 2% Of Ascorbic Acid (Vitamin C), Natural Flavor, Artificial Color, Yellow 5, BHA.
Study: NCT05366283

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor.
Study: NCT06326242

Intervention type: OTHER
Intervention: Solid Tumor
Description: The study focuses on defining the problem of geographical accessibility of patients to the Phase 1 facility of the European Institute of Oncology, based on anonymized data extraction from the enrolled patient database, to evaluate national territorial disparities in access to innovative experimental therapies, in relation to various socioeconomic determinants. Finally, relevant information on psychological factors for participation in clinical trials will also be collected.
Study: NCT04878133

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OCT - optical coherence tomography
Description: The principle by which OCT works is similar to ultrasound, although light waves close to infrared are used instead of ultrasounds.~In practice, the light waves, emitted into the vessel through a special catheter positioned in the coronary artery, meet the surrounding structures and are partly absorbed and partly reflected by them. The reflected waves are picked up by a sensor positioned on the catheter and analyzed through software that produces images visible live on a special console.
Study: NCT05769660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEY1107
Description: Administer twice daily, PO, 4-week continuous dose.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administer once daily, PO, 5-day continuous dose, followed by 23-day rest period.
Study: NCT05087615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: This groups only received metoclopramide 0.2 mg/kg IV Bid as antiemetic in the postoperative period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: This groups only received ondansetron 8 mg IV Bid as antiemetic in the postoperative period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide and Ondanteron
Description: This groups received both metoclopramide 0.2 mg IV Bid and ondansetron 8 mg IV/Bid as antiemetics in the postoperative period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: This groups only received granisetron 2 mg IV Bid as antiemetic in the postoperative period.
Study: NCT05464433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with Liposomal mitoxantrone hydrochloride
Description: Drug: liposomal mitoxantrone hydrochloride, tislelizumab Drug: Liposomal mitoxantrone hydrochloride (16 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: tislelizumab(200 mg) will be taken orally on day 1 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance of tislelizumab
Description: Drug: tislelizumab(200 mg) will be taken orally on day 1 of each 21-day cycle
Study: NCT05234580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA9159 nasal spray solution, 10 μg once daily for 14 days
Description: PA9159 of 10 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA9159 nasal spray solution, 20 μg once daily for 14 days
Description: PA9159 of 20 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA9159 nasal spray solution, 40 μg once daily for 14 days
Description: PA9159 of 40 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray solution without PA9159, once daily for 14 days
Description: Placebo nasal spray solution is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
Study: NCT04886934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CS1 System
Description: Placement of CS1, a temporary bipolar myocardial electrode (TME) with an integrated motion sensor (accelerometer), on the left ventricle and externalization of the associated leads through the chest wall during open-heart surgery. CS1 will remain in place for up to 7 days after surgery and closure of the chest wall.
Study: NCT05197803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aid model
Description: Amplification
Study: NCT05495204

Intervention type: DRUG
Intervention: Ibalizumab
Description: Participation in clinical trials vs. routine care in OPERA
Study: NCT05873348

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation (FMT) is the use of functional microorganisms in the feces of healthy people to form capsules and orally administer them to the intestinal tract of patients to reconstruct the intestinal flora of patients, so as to achieve the purpose of treating intestinal and exenteric diseases.
Study: NCT04390087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Upper-body rowing performed while participants are sitting in their own wheelchair.
Study: NCT05850208

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transplantation of self BMSCs
Description: Bone marrow was collected, cultured in vitro and injected back into the body
Study: NCT04723576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress First Aid
Description: Stress First Aid (SFA) is an evidence-based intervention to mitigate the psychosocial impact of COVID-19 on Health Care Workers (HCWs). SFA was initially developed for the United States Navy and Marine Corps as a framework of actions for peer support delivered by individuals without mental health training. SFA is designed to teach simple, supportive actions that can be seamlessly integrated into work environments. SFA training focuses on five essential principles: cover (restore and support a sense of safety), calm (encourage simple strategies such as breathing), connect (engage in and promote social support), competence (improve ability to address crucial needs and concerns), and confidence (increase hope and limit self-doubt and guilt). In this study, we are adapting the SFA model to include HCW-specific examples of SFA actions and case scenarios specific to the COVID-19 pandemic and will implement SFA using a train-the trainer model.
Study: NCT05042427

Intervention type: OTHER
Intervention: Pregnancy Weight Management Health Literacy Questionnaire
Description: Give questionnaires to check the weight management health literacy level of primigravida women.
Study: NCT05431257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Standard azacytidine treatment (AZA; D1-D7, 75mg/m2 qd) in combination with a short duration of low-dose venetoclax treatment (LD-VEN; D1-D14 before CR and D1-D7 after CR, 400mg qd) per 28 days cycle for elderly/unfit (arm 1) and relapsed/refractory (arm 2) patients with acute myeloid leukemia.